STSA 1201
Alternative Names: STSA-1201Latest Information Update: 21 Aug 2023
At a glance
- Originator Staidson Beijing BioPharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 07 Aug 2023 Phase I trial in Unspecified disease (In volunteers) in China (SC, Injection)(NCT05986877)